Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery ImQuest assisted with HBV neutralization assays to support the the recent publication in npj Vaccines. See the abstract below: Abstract While several COVID-19 vaccines have been in use, more effective and durable vaccines are needed to combat the ongoing COVID-19 pandemic. […]

Identification of a Non-Nucleoside Reverse Transcriptase Inhibitor against Human Immunodeficiency Virus-1 ImQuest assisted with HIV resistance and characterization assays to support the the recent publication in ACS Infection Disease. See the abstract below: Abstract The HIV-1 infection epidemic remains a global health problem. Current antiretroviral treatments are effective in controlling the progression of a severe […]

An allosteric inhibitor of sirtuin 2 deacetylase activity exhibits broad-spectrum antiviral activity ImQuest assisted with HBV primary human hepatocyte assays to support the the recent publication in the Journal of Clinical Investigation (JCI). See the abstract below: Abstract Most drugs used to treat viral disease target a virus-coded product. They inhibit a single virus or […]

Evybactin is a DNA gyrase inhibitor that selectively kills Mycobacterium tuberculosis ImQuest assisted with macr9molecular synthesis assays to support the the recent publication in Nature Chemical Biology. See the abstract below: Abstract The antimicrobial resistance crisis requires the introduction of novel antibiotics. The use of conventional broad-spectrum compounds selects for resistance in off-target pathogens and harms the […]

In Vitro Antiviral Profile of AB-343, a Novel, Oral, Potent SARS-CoV-2 MproInhibitor with Pan-coronavirus Activity ImQuest assisted with antiviral range of action analysis and SARS-CoV2 screening which was recently presented at ICAR 2023. Click Here to view. Contact us to learn more about about our broad range of antiviral testing services.

EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model ImQuest assisted antiviral testing for a recent publication in PLOS Pathogens. See the abstract below: Abstract EDP-938 is a novel non-fusion replication inhibitor of respiratory syncytial virus (RSV). It is highly active against all RSV-A and […]

Designing Dual Compartment HIV Prevention Products: Women’s Sensory Perceptions and Experiences of Suppositories for Rectal and Vaginal Use ImQuest published an article in AIDS Research and Human Retroviruses . See the abstract below: Abstract Dual compartment suppositories are being developed to prevent HIV and other sexually transmitted infections. Such products, for use in the rectum, […]

Publication highlights ImQuest’s Microbiology Capabilities Data produced by ImQuest’s team was recently highlighted in mBio (an ASM Journal). ImQuest BioSciences has a strong track record of working our clients to accelerate their research and development needs, and produce publication quality data as part of these services. As noted in Shahsavari et al, “Macromolecular incorporation assay […]

Top 50 Frederick Robert ‘Bobby’ Buckheit III has been recognized as one of Frederick’s Top 50 Professionals Under 40 by the Frederick County Office of Economic Development in partnership with Frederick Magazine. Bobby is Director of Sales & Business Development and a Manager of Immunology and Flow Cytometry Services at ImQuest BioSciences Inc. During the […]

In vitro effect of a non-immunosuppressive FKBP ligand, FK1706, on SARS-CoV-2 replication in combination with antivirals ImQuest assisted with studies to support the preprint of the following article. See the abstract below: Abstract FKBP, a naturally occurring ubiquitous intracellular protein, has been proposed as a potential target for coronavirus replication. A non-immunosuppressive FKBP ligand, FK1706, […]

Multi-marker Analysis of Anti-HBV Products Utilizing Primary Human Hepatocytes ImQuest BioSciences has developed and optimized a novel antiviral screening assay for hepatitis B virus (HBV) in primary human hepatocytes. This assay allows the simultaneous assessment of multiple markers of HBV replication, thus offering a unique method to assess both product efficacy and mechanism of action. […]

Novel Cyclophilin Inhibitor Decreases Cell Proliferation and Tumor Growth in Models of Hepatocellular Carcinoma ImQuest assisted with primary cell in vitro toxicity testing to support the the recent publication in Cancers. See the abstract below: Abstract Hepatocellular carcinoma (HCC), the most common primary liver cancer, is usually diagnosed in its late state. Tyrosine kinase inhibitors […]

The structure-activity profile of mercaptobenzamides’ anti-HIV activity suggests that thermodynamics of metabolism is more important than binding affinity to the target ImQuest was a key contributor to a recently published article in the European Journal of Medicinal Chemistry. See the abstract below: Abstract Mercaptobenzamide thioesters and thioethers are chemically simple HIV-1 maturation inhibitors with a […]

Coronavirus Drug Discovery and Development As part of the international effort to slow and combat the spread of pandemic COVID-19, ImQuest BioSciences has testing capability to assess novel and repurposed antiviral therapeutic and prevention products for activity against coronaviruses. With BSL-2 and BSL-3 strains available for testing, with capacity for both targeted testing, range of action assessments, […]

ImQuest Participates in International HBV Meeting Members of ImQuest BioSciences’ scientific team recently attended the International HBV Meeting in Paris, France. The annual meeting sponsored by the Hepatitis B Foundation, focused on the molecular biology of HBV and the development of novel treatment strategies to combat the virus to achieve the challenge of functional cure. […]

Synthesis and Antiviral Activity of a Series of 2′-C-Methyl-4′-thionucleoside Monophosphate Prodrugs ImQuest assisted with efficacy and cytotoxicity assays to support the the recent publication in Molecules. See the abstract below: Abstract The NS5B RNA-dependent RNA polymerase of the hepatitis C virus (HCV) is a validated target for nucleoside antiviral drug therapy. We endeavored to synthesize […]

Immune-Mobilizing Monoclonal T Cell Receptors Mediate Specific and Rapid Elimination of Hepatitis B–Infected Cells ImQuest assisted providing the highly concentrated HepG2.2.15 derived HBV stocks to support the the recent publication in the Hepatology. See the abstract below: Abstract ImmTAV molecules specific for HLA-A*02:01-restricted epitopes from HBV envelope, polymerase, and core antigens were engineered. The ability […]

Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs against Human Coronavirus 229E (HCoV-229E) ImQuest assisted with production and concentration of respiratory viruses and BSL-2 coronaviruses in a publication Molecules: Abstract Remdesivir is a nucleotide prodrug that is currently undergoing extensive clinical trials for the treatment of COVID-19. The prodrug is metabolized to its active […]

Inhibition of HBV replication by N-hydroxyisoquinolinedione and N-hydroxypyridinedione ribonuclease H inhibitors ImQuest was recently part of a publication that assessed the effects of novel antibacterial molecules, published in Antiviral Research: Abstract We recently developed a screening system capable of identifying and evaluating inhibitors of the Hepatitis B virus (HBV) ribonuclease H (RNaseH), which is the […]

Combination Therapy Key to Fighting Bacterial Infections A recent report in the scientific literature indicates that complex multi-drug combinations of antibiotics could be the key to fighting deadly bacteria. Current antibiotic treatments include using one or two drugs to fight an infection, and these treatments are becoming less and less effective as bacteria and other [...]